Novonix (NVX) submits Form 6-K with Appendix 2A on securities

Rhea-AI Filing Summary

Novonix Limited filed a Form 6-K as a foreign private issuer for December 2025. The filing mainly forwards an exhibit, Appendix 2A, which is an application for quotation of securities dated December 18, 2025. The report is signed by the Chief Financial Officer, Robert Long.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2025

001-41208

(Commission File Number)

NOVONIX LIMITED

(Translation of registrant’s name into English)

Level 38

71 Eagle Street

Brisbane, QLD 4000 Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40‑F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit No.		Description
Exhibit 99.1		Appendix 2A (Application for quotation of securities) dated December 18, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVONIX LIMITED
By:	/s/ Robert Long
	Robert Long
	Chief Financial Officer

Date: December 19, 2025

FAQ

What did Novonix (NVX) report in its December 2025 Form 6-K?

Novonix reported a Form 6-K for December 2025 primarily to furnish Exhibit 99.1. This exhibit is Appendix 2A, an application for quotation of securities dated December 18, 2025, signed on the company’s behalf by its Chief Financial Officer.

What is Exhibit 99.1 in Novonix (NVX) December 2025 Form 6-K?

Exhibit 99.1 is Appendix 2A, described as an Application for quotation of securities dated December 18, 2025. It is the key exhibit attached to the Form 6-K, indicating administrative steps related to seeking quotation for certain securities.

Who signed Novonix (NVX) December 2025 Form 6-K?

The Form 6-K was signed on behalf of Novonix Limited by Robert Long, its Chief Financial Officer. His signature confirms the company’s authorization of the filing under the Securities Exchange Act of 1934 for the December 2025 reporting month.

What type of issuer is Novonix (NVX) in this Form 6-K filing?

Novonix is identified as a foreign private issuer in this Form 6-K. The report is submitted under Rules 13a-16 or 15d-16 of the Securities Exchange Act of 1934, which govern periodic information furnished by foreign private issuers.

Which address is listed for Novonix (NVX) in the December 2025 Form 6-K?

The filing lists Novonix Limited’s principal executive office at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia. This address identifies the company’s main corporate location for regulatory and investor reference within the report.